Restoring the p53 ‘Guardian’ Phenotype in p53-Deficient Tumor Cells with CRISPR/Cas9
Open accessAbstract
With an increasing prevalence in the human population, cancer has become one of the most investigated fields of medicine. Among the potential targets for cancer therapy is the tumor suppressor gene TP53, which is found in a mutated state in approximately 50% of human cancers and is often associated with poor prognosis. We propose a novel, highly tumor-specific delivery system for TP53, based on the CRISPR/Cas9 genome editing technology. This system will restore the normal p53 phenotype in tumor cells by replacing the mutant TP53 gene with a functional copy, leading to sustained expression of p53 protein and tumor regression.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Chira's group proposed tumor-specific delivery of TP53 to replace mutant TP53 with a functional copy in tumor cells, resulting in sustained expression of p53 protein and tumor regression.
“In 2019, Chira’s group proposed an innovative idea for the highly tumor-specific delivery of TP53 to replace the mutant TP53 gene with a functional copy in tumor cells, resulting in sustained expression of the undruggable p53 protein and tumor regression.581”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [581]
The citation lists haven’t been fetched yet
References 57 · Cited by 56
- Authors
- Chira, S., Gulei, D., Hajitou, A., & Berindan-Neagoe, I.
- Affiliations
- Iuliu Hațieganu University of Medicine and Pharmacy (RO)
- Imperial College London (GB)
- Corresponding author
- Chira, Sergiu
- Venue
- Trends in Biotechnology
- Publisher
- Elsevier BV
- Published
- 2018-07
- Volume
- 36
- Issue
- 7
- Pages
- 653-660
- ISSN
- 0167-7799 (ISSN-L)
- OpenAlex
- W2787991539
- Semantic Scholar
- 76f8bcde8d584f4c1cb0ea34be7ed59c7941dc5b
- Cited by
- 56
- References
- 57
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 2 · 2023: 3 · 2022: 12 · 2021: 5 · 2020: 7 · 2019: 8 · 2018: 10
- FWCI
- 0.74
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- Trends in biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Spiral (Imperial College London) (submittedVersion, cc-by-nc-nd)
- Funders
- national grants (PN-III-P4-ID-PCE-2016-079, 164/2017, 35/01.09.2016, ID 37_796)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- TP53, p53 restoration, CRISPR/Cas9 genome editing, tumor suppressor, mutant TP53, tumor-specific gene delivery, cancer therapy, tumor regression, gene replacement
- MeSH terms
- Gene Editing, CRISPR-Associated Protein 9, Animals, Disease Models, Animal, Genetic Vectors, Humans, Mutation, Neoplasms, Prognosis, Genetic Therapy, Tumor Suppressor Protein p53, Mice, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
